Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Sanofi
|
| gptkbp:acquired |
gptkb:Sanofi
|
| gptkbp:acquisition |
gptkb:2011
Genzyme Corporation acquired by Sanofi in 2011 |
| gptkbp:awards |
Awards for research excellence
Recognized for workplace culture Awards for corporate social responsibility Received accolades for patient care Recognized for innovation in biotechnology |
| gptkbp:ceo |
gptkb:David_Meeker
|
| gptkbp:clinical_trial |
Conducts clinical trials for new therapies
Collaborates with research institutions for trials Engages in post-marketing studies. Focus on innovative treatment approaches Involved in research for rare diseases |
| gptkbp:employees |
~10,000 (2011)
|
| gptkbp:focus_area |
gptkb:healthcare_organization
Immunology Kidney disease Multiple sclerosis Cardiovascular disease Neurology Endocrinology Rare diseases |
| gptkbp:founded |
gptkb:1981
|
| gptkbp:founder |
gptkb:Henri_Termeer
|
| gptkbp:global_presence |
Operates in multiple countries
Has facilities in Asia Has facilities in Europe Has facilities in North America Serves patients worldwide |
| gptkbp:headcount |
~10,000
|
| gptkbp:headquarters |
gptkb:Cambridge,_MA
gptkb:Cambridge,_Massachusetts |
| https://www.w3.org/2000/01/rdf-schema#label |
Genzyme Corporation
|
| gptkbp:industry |
gptkb:Company
|
| gptkbp:market_cap |
$20 billion (2011)
|
| gptkbp:parent_company |
gptkb:Sanofi
|
| gptkbp:part_of |
gptkb:Sanofi_Group
|
| gptkbp:partnerships |
Collaborations with academic institutions
Collaborations with healthcare providers Partnerships with patient advocacy groups Partnerships with other biotech companies |
| gptkbp:philanthropy |
Supports various health initiatives
Involved in community health programs Contributes to rare disease research Engages in global health efforts Supports educational initiatives in biotechnology |
| gptkbp:products |
gptkb:Cerezyme
gptkb:Myozyme gptkb:Synvisc |
| gptkbp:research_and_development |
Significant investment in R& D
|
| gptkbp:revenue |
$4.5 billion (2011)
$4.5 billion (2010) |
| gptkbp:services |
Genetic testing
Enzyme replacement therapy |
| gptkbp:specializes_in |
rare diseases
|
| gptkbp:subsidiary |
gptkb:Genzyme_Genetics
gptkb:Genzyme_Biosurgery gptkb:Genzyme_Pharmaceuticals |
| gptkbp:website |
www.genzyme.com
|